The evaluation of the efficacy of sitagliptin for NASH/NAFLD patients-a multicenter open-label study-

The evaluation of the efficacy of sitagliptin for NASH/NAFLD patients-a multicenter open-label study- - The treatment with sitagliptin for NASH/NAFLD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005349

Enrollment

Registered

2011-03-30

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Interventions

sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) type 2 diabetic patients without medicines for 3 months 2) ALT more than 30 IU/L, in spite of dietary educations 3) patients, who were diagnosed as NASH/NAFLD on the basis of liver histology

Exclusion criteria

Exclusion criteria: 1) drinkers (ethanol intake > 20g/day) 2) HBsAg and/or HCV Ab positive patients

Design outcomes

Primary

Measure	Time frame
the findings of liver histology	—

Secondary

Measure	Time frame
improvement in liver function and diabetes	—

Countries

Japan

Contacts

Public ContactYoshio Sumida

Nara City Hospital Center for Digestive and Liver Diseases

sumida@nara-jadecom.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026